| Name | Title | Contact Details |
|---|
Have a Heart`s core mission is to provide the medical, psychological and social benefits of one of the world`s oldest and safest medicines to those in need and to those looking for a safer alternative to alcohol and prescription and illicit drugs. Our goal is to do this in a manner that is innovative, legal and compliant and that provides the most wonderful experience for our guests, our employees and the community overall. We focus on improving the local aesthetic, reducing crime and providing employment to those seeking legitimate employment in the cannabis industry. We believe in providing our customers with the highest quality product in a comfortable, professional and safe environment. All of our locations are unique and have been designed for the comfort and entertainment of our customer. Our friendly and knowledgeable team is always willing to answer any questions, so you`ll find the correct product for your needs. At Have a Heart we have taken many steps to ensure that our customers feel the trust and passion for excellence they deserve.
Entelo applies intelligence to big data to help modern recruiters identify, qualify and engage talent. Today, more than 700 customers of all sizes and industries trust Entelo to provide their talent acquisition teams with higher candidate engagement, actionable insights and increased productivity. The leader in recruiting automation, Entelo helps organizations like Capital One, Cisco, GE, Genentech, Netflix, Northrop Grumman and Target build their teams.
Theravance, Inc. is focused on maximizing the potential value of the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R), with the intention of providing capital returns to stockholders. Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement with GSK, Theravance is eligible to receive the associated royalty revenues from RELVAR(R)/BREO(R) ELLIPTA(R) (fluticasone furoate/vilanterol, "FF/VI"), ANORO(R) ELLIPTA(R) (umeclidinium bromide/vilanterol, "UMEC/VI") and if approved and commercialized, VI monotherapy. Theravance is also entitled to a 15% economic interest in any future payments made by GSK under agreements entered into prior to the spin-off of Theravance Biopharma, and since assigned to Theravance Respiratory Company, LLC, relating to the combination of UMEC/VI/FF and the Bifunctional Muscarinic Antagonist-Beta2 Agonist (MABA) program, as monotherapy and in combination with other therapeutically active components, such as an inhaled corticosteroid, and any other product or combination of products that may be discovered and developed in the future under these agreements with GSK (other than RELVAR(R)/BREO(R) ELLIPTA(R), ANORO(R) ELLIPTA(R) and VI monotherapy).
Ikaria is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
Optibrium provides elegant software solutions for small molecule design, optimisation and data analysis. Optibrium`s lead product, StarDrop™, is a comprehensive suite of integrated software with a highly visual and user-friendly interface. StarDrop™ enables a seamless flow from the latest data through to predictive modelling and decision-making regarding the next round of synthesis and research, improving the speed, efficiency, and productivity of the discovery process. The company`s new Augmented Chemistry™ products and services deliver ground-breaking artificial intelligence technologies that continuously learn from all available data to supplement your experience and skills. Founded in 2009, Optibrium is headquartered in Cambridge, UK with offices in Boston and San Francisco, USA. Optibrium continues to develop new products and research novel technologies to improve the efficiency and productivity of the drug discovery process. Optibrium works closely with its broad range of customers and collaborators that include leading global pharma, agrochemical and flavouring companies, biotech and academic groups.